Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORE-001: Cretostimogene Grenadenorepvec + Pembrolizumab in NMIBC
NCT04387461Phase 2Completed
- Sponsor
- CG Oncology, Inc.
- Start
- Dec 2020
- Primary completion
- Mar 2023
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 2
01
Overview
A Phase 2 trial of cretostimogene grenadenorepvec in non-muscle-invasive bladder cancer (NMIBC), sponsored by CG Oncology, Inc.. Started Dec 2020; status: completed.
02
Drugs
cretostimogene grenadenorepvec
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT04387461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04387461.